截至2025年8月7日15时，凯莱英股价报107.20元，较前一交易日下跌2.58元。当日成交量为89625手，成 交额达9.73亿元，换手率为2.83%。 风险提示：股市有风险，投资需谨慎。 公司首席运营官张达近期表示，中国药企正以更高效率和更低成本形成创新竞争力，未来5到10年将有 更多全球重磅药物来自中国。数据显示，2025年上半年中国药企海外BD交易金额达600亿美元，超过 2024年全年总量。 8月7日凯莱英主力资金净流出16957.47万元，占流通市值0.5%。近五日主力资金累计净流出46388.26万 元，占流通市值1.36%。 凯莱英是一家医药研发服务企业，主营业务涵盖创新药研发生产服务、制剂研发生产服务及临床研究服 务等。公司所属行业为医疗服务板块。 ...

Core Viewpoint - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index has shown a decline of 20.89% over the past month, while it has increased by 1.05% over the last three months and decreased by 2.89% year-to-date [1] Group 1: Index Performance - The CSI Hong Kong-Shanghai-Macau Pharmaceutical R&D Service Index is currently at 1344.91 points [1] - The index was established on December 29, 2017, with a base point of 1000.0 [1] Group 2: Index Composition - The top ten weighted companies in the index are: WuXi Biologics (18.47%), WuXi AppTec (13.28%), Hangzhou Tigermed Consulting (7.0%), and others [1] - The index consists of no more than 50 listed companies providing drug research, development, and production services [1] Group 3: Market Distribution - The market distribution of the index holdings is as follows: Shenzhen Stock Exchange (35.66%), Shanghai Stock Exchange (32.49%), and Hong Kong Stock Exchange (31.85%) [1] Group 4: Industry Breakdown - The industry composition of the index holdings includes: Pharmaceutical and Biotechnology Services (86.14%), Chemical Drugs (11.95%), Agricultural Chemicals (1.39%), and Biopharmaceuticals (0.52%) [2] Group 5: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Special circumstances may lead to temporary adjustments of the index [2]